The Bully Pulpit in Action: Cipro and Zevalin

 
• By Michael McCaughan

Former HHS Secretary Thompson's negotiation of a price discount on Bayer's antibiotic Cipro during the anthrax scare of 2001 is everybody's favorite example of price negotiation in action. The real lesson of that case, though, is that negotiation can pay off for manufacturers. For a less rosy example, consider Biogen Idec's experience with Zevalin.

Democrats have a favorite example of the power of the Secretary of Health & Human Services to negotiate lower drug prices: former Secretary Tommy Thompson’s agreement with Bayer AG to increase the US government’s stockpile of ciprofloxacin (Cipro) in response to the anthrax attacks in October 2001.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Non-Submissions To UK HTA Body Could Increase Unless Commercial Environment Improves, Warns Industry

 
• By Leela Barham

Finding ways to lower the rebates paid by the pharmaceutical industry to the UK government and fostering partnerships to make the UK a more attractive launch market could help reduce the number of terminated technology appraisals conducted by NICE, the health technology appraisal institute, says the UK pharmaceutical industry.

Non-Submissions To England’s NICE Surge Across All Disease Areas

 
• By Leela Barham

Blood cancer therapies were most proportionately impacted by the failure of pharmaceutical companies to submit evidence on their cancer therapies to England’s health technology appraisal body, shows analysis by the Pink Sheet.

PBMs No Longer Profit From Rebates But Plans Benefit; Should Sponsors Push More For Reform?

 
• By Cathy Kelly

Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.